Does infliximab infusion impact results of operative treatment for Crohn's perianal fistulas?

Diseases of the Colon and Rectum

Volumn 50, Issue 11, 2007, Pages 1754-1760

  Gaertner, Wolfgang B ^a   Decanini, Alejandra ^a   Mellgren, Anders ^a   Lowry, Ann C ^a   Goldberg, Stanley M ^a   Madoff, Robert D ^a   Spencer, Michael P ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Crohn's disease; Fistula; Infliximab; Perianal; Surgery

Indexed keywords

AZATHIOPRINE; CIPROFLOXACIN; FIBRIN GLUE; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; PREDNISONE; SALAZOSULFAPYRIDINE;

ADOLESCENT; ADULT; AGED; ALLERGIC REACTION; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DEEP VEIN THROMBOSIS; DRUG EFFICACY; FEMALE; FOLLOW UP; HERPES SIMPLEX ENCEPHALITIS; HUMAN; INTESTINE PERFORATION; MAJOR CLINICAL STUDY; MALE; MUSCLE WEAKNESS; PERIANAL FISTULA SURGERY; RECTUM FISTULA; RECTUM RESECTION; RECURRENT DISEASE; SETON DRAINAGE; SURGICAL DRAINAGE; SURGICAL TECHNIQUE; WOUND HEALING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; COMBINED MODALITY THERAPY; CROHN DISEASE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; RECTAL FISTULA;

EID: 35949002808     PISSN: 00123706     EISSN: 15300358     Source Type: Journal    
DOI: 10.1007/s10350-007-9077-3     Document Type: Article

References (44)

1. Schwartz DA, Loftus EV Jr, Tremaine WJ, et al. The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology 2002;122:875-80.
2. Williams JG, MacLeod CA, Rothenberger DA, Goldberg SM. Seton treatment of high anal fistulae. Br J Surg 1991;78:1159-61.
3. Sohn N, Korelitz BI, Weinstein MA. Anorectal Crohn's disease: definitive surgery for fistulas and recurrent abscesses. Am J Surg 1980;139:394-7.
4. van Deventer SJ. Tumour necrosis factor and Crohn's disease. Gut 1997;40:443-8.
5. Brynskov J, Nielsen OH, Ahnfelt-Ronne I, Bendtzen K. Cytokines (immunoinflammatory hormones) and their natural regulation in inflammatory bowel disease (Crohn's and ulcerative colitis): a review. Dig Dis 1994;12:290-304.
6. Braegger CP, Nicholls S, Murch SH, Stephens S, MacDonald TT. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992;339:89-91.
7. Reimund J-M, Wittershiem C, Dumont S, et al. Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn's disease. J Clin Immunol 1996;16:144-50.
8. Breese EJ, Michie CA, Nicholls SW, et al. Tumour necrosis factor-a producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994;106:1455-66.
9. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-35.
10. Regueiro M, Mardini H. Treatment of perianal fistulizing Crohn's disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement. Inflamm Bowel Dis 2003;9:98-103.
11. Talbot C, Sagar PM, Johnston MJ, Finan PJ, Burke D. Infliximab in the surgical management of complex fistulating anal Crohn's disease. Colorectal Dis 2005;7:164-8.
12. Van Assche G, Vanbeckevoort D, Bielen D, et al. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease. Am J Gastroenterol 2003;98:332-9.
13. van der Hagen SJ, Baeten CG, Soeters PB, Russel MG, Beets-Tan RG, van Gemert WG. Anti-TNF-alpha (infliximab) used as induction treatment in case of active proctitis in a multistep strategy followed by definitive surgery of complex anal fistulas in Crohn's disease: a preliminary report. Dis Colon Rectum 2005;48:758-67.
14. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405.
15. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350:876-85.
16. Topstad DR, Panaccione R, Heine JA, Johnson DR, MacLean AR, Buie WD. Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn's disease: a single center experience. Dis Colon Rectum 2003;46:577-83.
17. Hyder SA, Travis SP, Jewell DP, McC Mortensen NJ, George BD. Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment. Dis Colon Rectum 2006;49:1837-41.
18. Nordgren S, Fasth S, Hulten L. Anal fistulas in Crohn's disease: incidence and outcome of surgical treatment. Int J Colorectal Dis 1992;7:214-8.
19. Sandborn WJ, Fazio VW, Feagan BG, Hanauer SB; American Gastroenterological Association Clinical Practice Committee. AGA technical review on perianal Crohn's disease. Gastroenterology 2003;125:1508-30.
20. Halme L, Sainio AP. Factors related to frequency, type, and outcome of anal fistulas in Crohn's disease. Dis Colon Rectum 1995;38:55-9.
21. Parks AG, Gordon PH, Hardcastle JD. A classification of fistula-in-ano. Br J Surg 1976;63:1-12.
22. Ursing B, Kamme C. Metronidazole for Crohn's disease. Lancet 1975;1:775-7.
23. Bernstein LH, Frank MS, Brandt LJ, Boley SJ. Healing of perineal Crohn's disease with metronidazole. Gastroenterology 1980;79:357-65.
24. Brandt LJ, Bernstein LH, Boley SJ, Frank MS. Metronidazole therapy for perineal Crohn's disease: a follow-up study. Gastroenterology 1982;83:383-7.
25. Jakobovits J, Schuster MM. Metronidazole therapy for Crohn's disease and associated fistulae. Am J Gastroenterol 1984;79:533-40.
26. Rhodes J, Bainton D, Beck P, Campbell H. Controlled trial of azathioprine in Crohn's disease. Lancet 1971;2:1273-6.
27. Korelitz BI, Present DH. Favorable effect of 6-mercaptopurine on fistulae of Crohn's disease. Dig Dis Sci 1985;30:58-64.
28. Markowitz J, Rosa J, Grancher K, Aiges H, Daum F. Long-term 6-mercaptopurine treatment in adolescents with Crohn's disease. Gastroenterology 1990;99:1347-51.
29. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 1980;302:981-7.
30. Present DH, Lichtiger S. Efficacy of cyclosporine in treatment of fistula of Crohn's disease. Dig Dis Sci 1994;39:374-80.
31. Hanauer SB, Smith MB. Rapid closure of Crohn's disease fistulas with continuous intravenous cyclosporine A. Am J Gastroenterol 1993;88:646-9.
32. Lowry PW, Weaver AL, Tremaine WJ, Sandborn WJ. Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment refractory Crohn's disease perianal fistulae. Inflamm Bowel Dis 1999;5:239-45.
33. Williams JG, Rothenberger DA, Nemer FD, Goldberg SM. Fistula-in-ano in Crohn's disease. Results of aggressive surgical treatment. Dis Colon Rectum 1991;34:378-84.
34. Vitton V, Gasmi M, Barthet M, Desjeux A, Orsoni P, Grimaud JC. Long-term healing of Crohn's anal fistulas with fibrin glue injection. Aliment Pharmacol Ther 2005;21:1453-7.
35. O'Connor L, Champagne BJ, Ferguson MA, Orangio GR, Schertzer ME, Armstrong DN. Efficacy of anal fistula plug in closure of Crohn's anorectal fistulas. Dis Colon Rectum 2006;49:1569-73.
36. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet 2002;359:1541-9.
37. Sands BE, Blank MA, Patel K, van Deventer SJ; ACCENT II Study. Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol 2004;2:912-20.
38. Bell SJ, Halligan S, Windsor AC, Williams AB, Wiesel P, Kamm MA. Response of fistulating Crohn's disease to Infliximab treatment assessed by magnetic resonance imaging. Aliment Pharmacol Ther 2003;17:387-93
39. Ardizzone S, Maconi G, Colombo E, Manzionna G, Bollani S, Bianchi Porro G. Perianal fistulae following infliximab treatment: clinical and endosonographic outcome. Inflamm Bowel Dis 2004;10:91-6.
40. Van Bodegraven AA, Sloots CE, Felt-Bersma RJ, Meuwissen SG. Endosonographic evidence of persistence of Crohn's disease related fistulas after Infliximab treatment, irrespective of clinical response. Dis Colon Rectum 2002;5:39-45.
41. Rutgeerts P. Management of perianal Crohn's disease. Can J Gastroenterol 2000;14(Suppl C):7C-12C.
42. Ljung T, Karlen P, Schmidt D, et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 2004;53:849-53.
43. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo Clinic experience in 500 patients. Gastroenterology 2004;126:19-31.
44. Giles JT, Bartlett SJ, Gelber AC, et al. Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. Arthritis Rheum 2006;55:333-7.